Insight Molecular Diagnostics Inc. Common Stock IMDX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$103K+5.5% | -$109K+3.5% | -$113K+1.7% | -$115K-17.3% | -$98K-16.7% | ||
| $1.95M-51.9% | $4.06M-7.9% | $4.4M+3.4% | $4.26M+10.8% | $3.84M+104% | ||
| $949K-45.6% | $1.75M-11.5% | $1.97M+4.1% | $1.89M+7.7% | $1.76M+66.9% | ||
| $1M-56.7% | $2.31M-5.0% | $2.43M+2.8% | $2.36M+13.3% | $2.09M+152% | ||
| 51.3%-5.7pp | 57%+1.7pp | 55.2%-0.3pp | 55.5%+1.3pp | 54.3%+10.3pp | ||
| $17.94M+12.8% | $15.91M+28.9% | $12.34M+9.4% | $11.28M+7.9% | $10.45M+6.2% | ||
| $7.54M+18.9% | $6.34M+20.7% | $5.25M+7.0% | $4.91M+14.1% | $4.3M+9.1% | ||
| $10.51M-1.2% | $10.63M-2.1% | $10.87M-0.2% | $10.89M+2.3% | $10.65M+4.3% | ||
| $49.74M-6.9% | $53.43M-16.1% | $63.73M-3.6% | $66.1M+9.1% | $60.59M-1.9% | ||
| $49.74M-6.9% | $53.43M-16.1% | $63.73M-3.6% | $66.1M+9.1% | $60.59M-1.9% | ||
| -$48.74M+4.7% | -$51.12M+16.6% | -$61.32M+3.9% | -$63.78M-8.9% | -$58.57M+4.0% | ||
| -2,500.7%-1,240pp | -1,260.8%+132pp | -1,392.9%+105pp | -1,498.3%+25.8pp | -1,524.1%+1,721pp | ||
| $897K-0.6% | $902K+67.7% | $538K+47.0% | $366K-0.5% | $368K-2.6% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| -$47.84M+4.7% | -$50.22M+17.4% | -$60.78M+4.2% | -$63.42M-9.0% | -$58.21M+4.1% | ||
| -2,454.6%-1,216pp | -1,238.5%+142pp | -1,380.7%+109pp | -1,489.7%+24.9pp | -1,514.6%+1,710pp | ||
| -$1.50+8.5% | -$1.64+48.8% | -$3.20+16.7% | -$3.84+1.5% | -$3.90+18.2% | ||
| -$1.50+8.5% | -$1.64+48.8% | -$3.20+16.7% | -$3.84+1.5% | -$3.90+18.2% | ||
| 129.1M+7.3% | 120.2M+16.9% | 102.8M+21.7% | 84.5M+29.3% | 65.3M+36.4% | ||
| 129.1M+7.3% | 120.2M+16.9% | 102.8M+21.7% | 84.5M+29.3% | 65.3M+36.4% | ||
| —— | —— | -$6.64M-131% | -$2.87M+57.2% | -$6.71M-56.9% | ||
| -$103K+5.5% | -$109K+3.5% | -$113K+1.7% | -$115K-17.3% | -$98K-16.7% | ||
| $1M-1.1% | $1.01M+55.3% | $651K+35.3% | $481K+3.2% | $466K+0.9% | ||
| $1.95M-51.9% | $4.06M-7.9% | $4.4M+3.4% | $4.26M+10.8% | $3.84M+104% | ||
| -$48.74M+4.7% | -$51.12M+16.6% | -$61.32M+3.9% | -$63.78M-8.9% | -$58.57M+4.0% | ||
| -$46.4M+5.2% | -$48.93M+17.3% | -$59.15M+4.4% | -$61.88M-8.7% | -$56.93M+4.4% | ||
| -$46.4M+5.2% | -$48.93M+17.3% | -$59.15M+4.4% | -$61.88M-8.7% | -$56.93M+4.4% | ||
| -2,380.8%-1,174pp | -1,206.8%+137pp | -1,343.7%+110pp | -1,453.6%+27.7pp | -1,481.3%+1,685pp | ||
| -$48.74M+4.7% | -$51.12M+16.6% | -$61.32M+3.9% | -$63.78M-8.9% | -$58.57M+4.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Insight Molecular Diagnostics Inc. Common Stock's revenue?
- Insight Molecular Diagnostics Inc. Common Stock (IMDX) generated $1.9M in revenue over the trailing twelve months, down 49.3% year over year.
- Is Insight Molecular Diagnostics Inc. Common Stock profitable?
- Insight Molecular Diagnostics Inc. Common Stock is not currently profitable: it reported a net loss of $47.8M over the trailing twelve months, a -2454.6% net margin.
- What are Insight Molecular Diagnostics Inc. Common Stock's profit margins?
- Gross margin is 51.3% and operating margin is -2500.7%, with a -2454.6% net margin.
- What is Insight Molecular Diagnostics Inc. Common Stock's earnings per share?
- Insight Molecular Diagnostics Inc. Common Stock's diluted EPS over the trailing twelve months is $-1.50.
- Where does Insight Molecular Diagnostics Inc. Common Stock's income statement data come from?
- Every line is extracted from Insight Molecular Diagnostics Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
